status of volunteers who have been enrolled previously in an IAVI-sponsored trial of an investigational HIV vaccine candidate.
participated in HIV vaccine clinical trials.
To evaluate the persistence of vaccine-induced antibodies in
volunteers who tested HIV positive at the end of the IAVI-sponsored vaccine trial.
To characterize immunological, virological, and immunogenetic
responses in volunteers participating in IAVI-sponsored clinical trials.
In 2006, IAVI and its Neutralizing Antibody Consortium launched the Protocol G project to search for bNAbs against HIV, partnering with clinical research centers in Africa, India, Thailand, Australia, the United Kingdom, and the United States. More than 1,800 healthy, HIV-positive volunteers contributed blood samples to be screened. In 2009, scientists from IAVI, The Scripps Research Institute, and Theraclone Sciences collaborated to isolate and characterize the first new bNAbs to HIV seen in a decade and the first to be isolated from donors in developing countries, where the majority of new HIV infections occur. To date, more than 25 new bNAbs have been isolated and characterized from Protocol G specimens, and many have been shared with researchers across the AIDS vaccine field.
- What We Do
- Where We Work
- Who We Are
- How To Help
- Information Center
- Donate Now